The three companies involved in the TransLink Project have recently received attention on public media due to recent news.
The most recent news is of Mind the Byte, which already was a pioneer in the use of artificial intelligence, cloud and big data for computational drug design, and has acquired 100% of Intelligent Pharma, one of the leading companies in Spain in chemoinformatics services for the pharmaceutical and biotechnology industry. With this operation -the largest corporate movement registered in the emerging Spanish bioinformatics market- Mind the Byte becomes the leading company at a national level and one of the largest in Europe in applying artificial intelligence to the discovery and development of new medicines.
Similarly, InKemia IUCT group has reach an agreement with the nearly Town Hall of Parets del Valles to create a company accelerator. The aim of InKemia will be able to incubate the spin-off companies created or the start-up InKemia is investing. The forecast is that the new headquarters of the IUCT Parets provide qualified jobs and attract international talent, encourage entrepreneurship, generate innovation to transfer to companies because they are more competitive, be a source of new ideas, boost investments to companies and create an attractive environment for the implementation of new technology companies. “We think that in ten years they will have incubated in these facilities between 50 and 75 companies, of which between 17 and 25 will grow a lot,” said Dr Castells, CEO of InKemia. “We also say that in ten years, between 200 and 575 jobs will have been generated,” he said. In the picture: The President of InKemia IUCT, Dr Josep Castells and the Parets del Valles Mayor Mr Sergi Mingote at the press conference.
Finally Avantea is continuing showing their Excellency in research. Last September 2017, its CEO Prof. Cesare Galli receives the AETE Pioneer Award during the 33rd annual convention of the European Embryo Technologies Association (AETE). This award recognises the important contributions Prof. Galli has made since the beginning of his thirty-year long career: first in Cambridge (UK) and then at the Laboratory of Reproduction Technologies (LTR) in Cremona now Avantea. The aim of AETE is to facilitate the diffusion and application of embryo technologies in mammals by creating a forum for the exchange of scientific, technical and practical knowledge at a European level and by organizing regular meetings that encourage the participation of scientists, professionals, technicians and students.
Avantea facilities hosted the 2017 Genome Editing Training Course dedicated to Genome Editing in Pigs for Xenotransplantation.
6 students from Spain, Italy, United Kingdom France where train in the fast evolving field of large animals’ genetic engineering, to foster interactions and promote the latest technology for genome editing in mammals with particular reference to genome editing for xenotransplantation.
The course covered the following themes: Requirements for xenotransplantation, Genetic engineering of large animals, Conception and design of genome editing nucleases, Editing in somatic cell cultures and selection of mutant cells, Somatic cell nuclear transfer to generate embryos for transfer to surrogates mothers and Birth of offspring and genetic analysis
The course features a series of introductory lectures followed by hands-on training:
The students gave the course an excellent overall evaluation remark the excellent organization and coordination.
Some of their comments:
“Very interesting lectures, easy to follow for beginners but also interesting for more advanced attendees.”
“The whole course more interesting than expected”
“Very interesting to understand all the steps involved in a xenotransplantation project.”
“Front lessons and practical part very well integrated”
An Translink open conference to the general public in Cremona
Organized by our partner Avantea in the Cremona Chamber of Commerce on May 17th, the objective of this conference was to bring public opinion to the topics of scientific research in the biomedical field with reference to cardiac pathologies. The conference addressed surgical and biotechnological aspects related to the prevention and treatment of the most frequent heart diseases. It will also offer a presentation on the process of developing new molecules for pharmacological use.
The speakers were scientists, university professors and executive directors of cutting-edge pharmaceutical and biomedical companies from 4 different countries. General public had the opportunity to explore different thematic areas related to scientific research and the experience of speakers. In particular, they were Tommaso Bottio (UNIPD), Jean Christian Roussel (CHU), Vered Padler-Karavani (TAU), Emanuele Cozzi (AOP), Cesare Galli(AVANTEA)and Marta Pasqual (IUCT)
The full conference was recorded and it is fully accessible on-line (in Italian).
Dr Vered Padler-Karavani From Tel-Aviv University has been awarded with an important grant from the European Research Council for the project entitled “Selective glycoimmuno-targeting for cancer therapy, SweetAim”,
SweetAim’s objective is to design a novel personalized cancer therapeutic approach based on xeno-autoantibodies against the dietary sugar antigen
Dr Padler-Karavani work is an innovative interdisciplinary approach crossing the boundaries of cancer research, glycosciences, immunology and nanotechnology, with cutting-edge technologies, to design, engineer, screen and fully investigate potent targeting of ‘SweetAim’ moieties.
The project will continue until late 2021 and have a budget of almost 1,5 million Euro which will allow Dr Padler-Karavani to become leader in Glycoimmunology
Genome Editing in Pigs for Xenotransplantation.
The TRANSLINK project funded by the European Commission 7th Framework Program will be hosting the “2017 Genome Editing Training Course” in Avantea facilities, Cremona, Italy on Monday May 15th through Wednesday May 17th. The goal of this meeting is to expose international students to the fast evolving field of large animals’ genetic engineering, to foster interactions and promote the latest technology for genome editing in mammals using CRISPR/Cas9 with particular reference to genome editing for xenotransplantation. The course will feature a series of introductory lectures followed by hands-on training.
The course will cover these major themes:
- Requirements for xenotransplantation
- Genetic engineering of large animals
- Conception and design of genome editing nucleases
- Editing in somatic cell cultures and selection of mutant cells
- Somatic cell nuclear transfer to generate embryos for transfer to surrogates mothers
- Birth of offspring and genetic analysis
Visit the training course web page: http://www.translinkproject.com/training-course-2017/
On the 9th of November 2016, the European Collaborative projects TransLink and Xenoislet joined together in a public dissemination event: the Conference on “Research on animal-derived products for use in the clinic – Results from EU collaborative projects”.
Students and international professionals attended the iconic Wilkins Main Building at University College London and got key insights into xenotransplantation for both heart valve deterioration and diabetes treatment from the top experts in the fields.
The conference aimed to promote the international exchange of the latest concepts, innovative techniques and results in the field of cardiovascular valve transplantation, glycoimmunology, pancreatic islets and innovative diabetes treatment, offering participants the opportunity to interact with a number of outstanding scientific leaders and researchers.
Dr Emanuele Cozzi (Azienda Ospedaliera di Padova, Italy) (above, right) and Prof Pierre Gianello (Catholic University of Louvain, Belgium) (above, left), co-ordinators of TransLink and Xenoislet, respectively, led the Conference which gathered experts from hospitals, academia and companies focused on the research, understanding and creation of real solutions inheart valve pathology and diabetes.
Furthermore, the event was attended by Dr Charles Kessler, Research Directorate-General of the European Commission, who provided insight into the thinking of the European Commission and global challenges, as well as the importance of collaborative research for addressing such challenges.
Meet the experts behind our EU collaborative projects, discover their objectives and results:
- TransLink “Defining the role of xeno-directed and autoimmune events in patients receiving animal-derived bioprosthetic heart valves” and
- Xenoislet “Macroencapsulated Porcine Pancreatic Islets to cure Diabetes Mellitus type 1/2”
Angela Barone from University of Gothemborg (UGOT) will give a TranLink presentation on “Glycosphingolipids of porcine, bovine and equine pericards as potential immune targets in biological heart valve grafts” at the XXIIth Nordic Molecular Glycobiology Meeting in Copenhagen.
The meeting will be held during the 9th and 10th of December at University of Copenhagen. This offers an ideal opportunity for junior researchers to present their work in an informal atmosphere, and for researchers at all levels to network and discuss different aspects of glycobiology. The meeting accomodates about 80 participants from Sweden, Norway, Finland, Germany and Denmark, with 26 talks distributed over two days.
Here the agenda of the meeting
The European Association of Economy and Competitiveness give to Inkemia IUCT group the Gold Medal for Merit in Work in recognition of its professional trajectory, excellent labour during and experience in the Pharmaceutical sector and customer satisfaction for the service provided.
This ceremony was taken place in November at Hotel Westin Palace in Madrid. The distinctions were given by The president of honour of the European Association of Economy and Competitiveness, Hon. Myriam de la Sierra and Urquijo and the price was received by the director of Inkemia Madrid Dr Adrián García on behalf of the CEO Dr Josep Castells.
The Gold Medal for Merit in Work awarded by the AEEC represents excellence and entrepreneurship, contributing to a sustainable and inspiring entrepreneurial European environment, which fosters good economic and social development. By obtaining this award institutions may encourage communication in different professional sectors of convenience as well as a loyalty of your prospects.
This year Dr. Solillou from INSERM, has been awarded with the prestigious Medawar Prize of The Transplantation Society.
The Medawar Prize, named after Society co-founder Sir Peter Medawar, is recognized as the world’s highest dedicated award for the most outstanding contributions in the field of transplantation. The Medawar Prize has been awarded at each of our Society’s biennial Congresses since 1990.
The award recognizes the outstanding investigators whose contributions have had such a profound influence on the field of organ transplantation. The Medawar Prize is universally considered to be commensurate with the most outstanding world prizes for scientific achievement.
Next Wednesday, November 9th , University College London will host the important Joint Dissemination Event “Research on animal-derived products for use in the clinic – Results from EU collaborative projects”.
This event brings together two international projects, TransLink (www.translinkproject.com) and XenoIslet (http://xenoislet.eu), funded by the European Union’s Seventh Framework Programme for Research and Technological Development.
The conference aims to promote the international exchange of the latest concepts, innovative techniques and results in the field of cardiovascular valve transplantation, glycoimmunology, pancreatic islets and innovative diabetes treatment,offering participants the opportunity to
outstanding scientific leaders and researchers.
[for any further information, interested parties should refer to Prof Pierre Gianello, M.D., PhD. (firstname.lastname@example.org) or Dr Emanuele Cozzi, M.D., Ph.D. (Emanuele.email@example.com) who are the coordinators of the two FP7 EU-funded projects]